KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt to Equity (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Debt to Equity for 13 consecutive years, with $43.89 as the latest value for Q4 2025.

  • Quarterly Debt to Equity rose 960.53% to $43.89 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.89 through Dec 2025, up 960.53% year-over-year, with the annual reading at $43.89 for FY2025, 960.53% up from the prior year.
  • Debt to Equity for Q4 2025 was $43.89 at Halozyme Therapeutics, up from $3.0 in the prior quarter.
  • The five-year high for Debt to Equity was $43.89 in Q4 2025, with the low at $0.32 in Q3 2021.
  • Average Debt to Equity over 5 years is $8.2, with a median of $4.49 recorded in 2025.
  • The sharpest move saw Debt to Equity skyrocketed 6495.68% in 2023, then crashed 76.86% in 2024.
  • Over 5 years, Debt to Equity stood at $4.45 in 2021, then skyrocketed by 99.27% to $8.87 in 2022, then surged by 101.68% to $17.89 in 2023, then plummeted by 76.86% to $4.14 in 2024, then surged by 960.53% to $43.89 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $43.89, $3.0, and $4.54 for Q4 2025, Q3 2025, and Q2 2025 respectively.